Back to top
more

CollPlant Biotechnologies (CLGN)

(Delayed Data from NSDQ)

$5.00 USD

5.00
11,754

+0.04 (0.81%)

Updated Jul 3, 2024 12:55 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?

by Zacks Equity Research

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

New Strong Sell Stocks for April 22nd

by Zacks Equity Research

BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022

3D Systems (DDD) Joins CollPlant for Bioprinted Breast Tissue Matrix

by Zacks Equity Research

The collaborative efforts of 3D Systems (DDD) and CollPlant aim to eliminate the odds of adverse immune response in the human body induced by procedures using tissue derived from humans and animals.

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $14.68 in the latest trading session, marking a +1.91% move from the prior day.

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Stock Moves -0.22%: What You Should Know

by Zacks Equity Research

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $13.77 in the latest trading session, marking a -0.22% move from the prior day.

CollPlant (CLGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

CollPlant (CLGN) is set to report earnings and revenues, and provide product updates when it releases first-quarter 2021 results.

Is CollPlant Biotechnologies Ltd. Sponsored (CLGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (CLGN) Outperforming Other Medical Stocks This Year?

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $12.26 in the latest trading session, marking a -1.84% move from the prior day.

Has CollPlant Biotechnologies Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (CLGN) Outperforming Other Medical Stocks This Year?

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $13.33, marking a +1.76% move from the previous day.

The Zacks Analyst Blog Highlights: Cirrus Logic, HighPoint Resources Corp, Immersion Corp, CollPlant Biotechnologies and Suburban Propane Partners

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Cirrus Logic, HighPoint Resources Corp, Immersion Corp, CollPlant Biotechnologies and Suburban Propane Partners

Sejuti Banerjea headshot

6 Beaten Down Stocks with Solid Growth Potential

by Sejuti Banerjea

Are you going to sit around to try and price a bottom or are you going to grab stocks that look obviously cheap today?

USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Has CollPlant Holdings Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (CLGN) Outperforming Other Medical Stocks This Year?

Is CollPlant Holdings Ltd. Sponsored (CLGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (CLGN) Outperforming Other Medical Stocks This Year?

What Makes CollPlant Holdings Ltd. Sponsored ADR (CLGN) a New Strong Buy Stock

by Zacks Equity Research

CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CollPlant's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in CollPlant Biotechnologies.

Has CollPlant Holdings Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (CLGN) Outperforming Other Medical Stocks This Year?

3D Systems Joins CollPlant in Regenerative Medicine Efforts

by Zacks Equity Research

3D Systems (DDD) and CollPlant aim to create state-of-the-art 3D bioprinters and BioInks to produce tissues and scaffolds.

CollPlant Holdings Ltd. Sponsored ADR (CLGN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Top Ranked Momentum Stocks to Buy for October 11th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 11th.

Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2

by Zacks Equity Research

Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.

    VIVUS' PAH Candidate Data Positive in Early Stage Study

    by Zacks Equity Research

    VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

      Aclaris' Alopecia Candidate Gets Fast Track Designation

      by Zacks Equity Research

      The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.